⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10259106 | 0.74 | — | — | |
| SCHEMBL25149427 | 0.70 | MAP4K4 (0.33) | — | |
| SCHEMBL25148914 | 0.69 | DYRK1A (0.41) | — | |
| SCHEMBL520833 | 0.68 | — | — | |
| SCHEMBL10259107 | 0.68 | — | — | |
| SCHEMBL10970818 | 0.64 | KDM4E (0.35) | — | |
| SCHEMBL25150120 | 0.62 | IRAK4 (0.33) | — | |
| SCHEMBL20910334 | 0.60 | ACACB (0.37) | — | |
| SCHEMBL25150145 | 0.60 | — | — | |
| SCHEMBL14485538 | 0.59 | MAP4K4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415816-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250171466-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12134625-B2 | Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4415816-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118488954-A | Pyrrolo [2,1-F ] [1,2,4] triazine derivatives as DYRK1A inhibitors | 拜斯丽治疗有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230312605-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312605-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312605-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023064366-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064366-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |